Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Report Type

Organization

Disposition

Year

Month

Found 72808 record(s)

Req # A-2020-001153

Adverse Reaction Reports (AERs) for HYDROXYCHLOROQUINE SULFATE. Report numbers: E2B_03061164, E2B_03061214, E2B_03064558, E2B_03067077, E2B_03154905, E2B_03157311, E2B_03123930.

Organization: Health Canada

90 page(s)
February 2021

Req # A-2020-001174

Adverse Reaction Reports (AERs). Report numbers: E2B_02396410, E2B_02396651, E2B_02396724, E2B_02397078, E2B_02397199, E2B_02397202, E2B_02397228, E2B_02397798, E2B_02398866, E2B_02399023, E2B_02399064, E2B_02399428, E2B_02399708, E2B_02399709,…

Organization: Health Canada

381 page(s)
February 2021

Req # A-2020-001504

Adverse Drug Reaction (ADR) for Riva-Rosuvastatin. Report number: 000920995. ADR for Zevtera. Report number: 000920266.

Organization: Health Canada

7 page(s)
February 2021

Req # A-2020-001507

Adverse Drug Reaction (ADR). Report number: 000909105.

Organization: Health Canada

2 page(s)
February 2021

Req # A-2020-001182

Adverse Reaction Reports (AERs). Report numbers: E2B_02417794, E2B_02417839, E2B_02418123, E2B 02419266, E2B_02419267, E2B_02420129, E2B_02420380, E2B_02420387, E2B 02420403, E2B_02420408, E2B_02420409, E2B_02420413, E2B_02420468, E2B_02421443, E2B…

Organization: Health Canada

321 page(s)
February 2021

Req # A-2020-001230

Adverse Reaction Reports (AERs). Report numbers: E2B_02682195, E2B_02680873, E2B_02611042.

Organization: Health Canada

90 page(s)
February 2021

Req # A-2020-001320

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-110687-464, Publication of consumption incidents related to supplemented food, including caffeinated energy drinks.

Organization: Health Canada

12 page(s)
February 2021

Req # A-2020-001340

Adverse Drug Reaction (ADR) for DRONEDARONE. Report number: 738133.

Organization: Health Canada

4 page(s)
February 2021

Req # A-2020-001350

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-106853-419, Strategy for and governance of large-scale medical countermeasures including vaccine task force.

Organization: Health Canada

2 page(s)
February 2021

Req # A-2020-001487

Briefing note and/or briefing materials in the Ministerial Executive Correspondence System (MECS) for the following file: 20-100077-613, Telfer Leading Change Certificate Program.

Organization: Health Canada

18 page(s)
February 2021
Date modified: